Home › Funds › PFM Health Sciences, LP › CLDX
PFM Health Sciences, LP position in CLDX
CELLDEX THERAPEUTICS INC NEW · Health Care
PFM Health Sciences, LP reported holding 235,815 shares of CLDX (CELLDEX THERAPEUTICS INC NEW) in its Q3 2026 13F filing — a position valued at US$7.6M, representing 0.78% of its reported portfolio and ranking #48 among its reported holdings. PFM Health Sciences, LP has disclosed CLDX holdings in 8 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How PFM Health Sciences, LP's CLDX position evolved
PFM Health Sciences, LP first disclosed a stake in CLDX in Q4 2023 at 35,000 shares (US$1.4M). The position peaked in Q2 2026 at 342,751 shares, worth US$12.8M. Across 8 filings, PFM Health Sciences, LP increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 235,815 shares valued at US$7.6M — a reduction of -106,936 shares quarter over quarter.. Notable position changes include a 49% increase in Q2 2024 (shares fell 8% over the following quarter), a 144% increase in Q1 2026 (shares rose 17% over the following quarter), a 31% trim in Q3 2026 (shares fell 11% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 35.00K | $1.39M | New |
| Q1 2024 | 35.00K | $1.47M | Hold |
| Q2 2024 | 52.12K | $1.93M | Add |
| Q3 2024 | 52.12K | $1.77M | Hold |
| Q4 2025 | 133.16K | $3.62M | New |
| Q1 2026 | 324.96K | $10.31M | Add |
| Q2 2026 | 342.75K | $12.75M | Add |
| Q3 2026 | 235.81K | $7.64M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CLDX and 13F data
CLDX (CELLDEX THERAPEUTICS INC NEW) is a Health Care company. 40 other funds we track also report a position in CLDX — the largest reported positions include Kynam Capital Management, LP (US$164.2M), Deep Track Capital, LP (US$68.9M), EVENTIDE ASSET MANAGEMENT, LLC (US$61.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CLDX
- Kynam Capital Management, LP 5.07M sh · $164.19M · Q3 2026
- Deep Track Capital, LP 2.13M sh · $68.89M · Q3 2026
- EVENTIDE ASSET MANAGEMENT, LLC 1.90M sh · $61.46M · Q3 2026
- Commodore Capital LP 1.35M sh · $50.23M · Q2 2026
- Bellevue Group AG 1.20M sh · $44.65M · Q2 2026
- BAKER BROS. ADVISORS LP 1.18M sh · $44.00M · Q2 2026
- Novo Holdings A/S 1.02M sh · $38.14M · Q2 2026
- Eversept Partners, LP 1.17M sh · $38.07M · Q3 2026
- Affinity Asset Advisors, LLC 1.16M sh · $37.61M · Q3 2026
- Elmind Capital, LP 990.00K sh · $36.84M · Q2 2026
- Foresite Capital Management VI LLC 879.71K sh · $32.73M · Q2 2026
- ADAR1 Capital Management, LLC 799.30K sh · $25.91M · Q3 2026
More on PFM Health Sciences, LP
FAQ
How long has PFM Health Sciences, LP held CLDX?
PFM Health Sciences, LP has disclosed CLDX holdings in 8 of the last 12 reported quarters, going back to Q4 2023.
What is PFM Health Sciences, LP's current position in CLDX?
As of Q3 2026, PFM Health Sciences, LP holds 235.81K shares of CLDX (CELLDEX THERAPEUTICS INC NEW), valued at $7.64M, representing 0.78% of its reported portfolio and ranking #48.
Has PFM Health Sciences, LP been buying or selling CLDX?
In the latest 13F filing (Q3 2026), PFM Health Sciences, LP reduced its position in CLDX. The position peaked in Q2 2026 at 342.75K shares.
Which other funds hold CLDX?
Other major institutional holders of CLDX include Kynam Capital Management, LP, Deep Track Capital, LP, EVENTIDE ASSET MANAGEMENT, LLC, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.